Cargando…
Level of inflammatory cytokines tumour necrosis factor α, interleukins 12, 23 and 17 in patients with psoriasis in the context of metabolic syndrome
INTRODUCTION: Psoriasis is a chronic inflammatory skin disease with immunologic etiology. AIM: To investigate the levels of the proinflammatory cytokines tumor necrosis factor α (TNF-α), interleukin 23 (IL-23) and IL-17 in patients with psoriasis and psoriatic arthritis with concomitant metabolic sy...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6409868/ https://www.ncbi.nlm.nih.gov/pubmed/30858782 http://dx.doi.org/10.5114/ada.2018.73136 |
_version_ | 1783402090776756224 |
---|---|
author | Pirowska, Magdalena Podolec, Katarzyna Lipko-Godlewska, Sylwia Sułowicz, Joanna Brzewski, Paweł Obtułowicz, Aleksander Pastuszczak, Maciej Wojas-Pelc, Anna |
author_facet | Pirowska, Magdalena Podolec, Katarzyna Lipko-Godlewska, Sylwia Sułowicz, Joanna Brzewski, Paweł Obtułowicz, Aleksander Pastuszczak, Maciej Wojas-Pelc, Anna |
author_sort | Pirowska, Magdalena |
collection | PubMed |
description | INTRODUCTION: Psoriasis is a chronic inflammatory skin disease with immunologic etiology. AIM: To investigate the levels of the proinflammatory cytokines tumor necrosis factor α (TNF-α), interleukin 23 (IL-23) and IL-17 in patients with psoriasis and psoriatic arthritis with concomitant metabolic syndrome. MATERIAL AND METHODS: This study included 60 patients with severe psoriasis. RESULTS: In patients with arterial hypertension concomitant with psoriasis, no statistically significant differences in cytokine levels were observed. On the other hand, in the group of patients diagnosed with diabetes, an increased level of IL-17 was observed. In patients with lipid disorders, the results were similar to the results of patients with diabetes. CONCLUSIONS: It is very important to study immunologic mechanisms responsible for the presence and severity of psoriasis, in order to personalize the therapy in the future and optimize the effect of action on the basic disease and on concomitant disorders. |
format | Online Article Text |
id | pubmed-6409868 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Termedia Publishing House |
record_format | MEDLINE/PubMed |
spelling | pubmed-64098682019-03-11 Level of inflammatory cytokines tumour necrosis factor α, interleukins 12, 23 and 17 in patients with psoriasis in the context of metabolic syndrome Pirowska, Magdalena Podolec, Katarzyna Lipko-Godlewska, Sylwia Sułowicz, Joanna Brzewski, Paweł Obtułowicz, Aleksander Pastuszczak, Maciej Wojas-Pelc, Anna Postepy Dermatol Alergol Original Paper INTRODUCTION: Psoriasis is a chronic inflammatory skin disease with immunologic etiology. AIM: To investigate the levels of the proinflammatory cytokines tumor necrosis factor α (TNF-α), interleukin 23 (IL-23) and IL-17 in patients with psoriasis and psoriatic arthritis with concomitant metabolic syndrome. MATERIAL AND METHODS: This study included 60 patients with severe psoriasis. RESULTS: In patients with arterial hypertension concomitant with psoriasis, no statistically significant differences in cytokine levels were observed. On the other hand, in the group of patients diagnosed with diabetes, an increased level of IL-17 was observed. In patients with lipid disorders, the results were similar to the results of patients with diabetes. CONCLUSIONS: It is very important to study immunologic mechanisms responsible for the presence and severity of psoriasis, in order to personalize the therapy in the future and optimize the effect of action on the basic disease and on concomitant disorders. Termedia Publishing House 2019-02-02 2019-02 /pmc/articles/PMC6409868/ /pubmed/30858782 http://dx.doi.org/10.5114/ada.2018.73136 Text en Copyright: © 2019 Termedia Sp. z o. o. http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license. |
spellingShingle | Original Paper Pirowska, Magdalena Podolec, Katarzyna Lipko-Godlewska, Sylwia Sułowicz, Joanna Brzewski, Paweł Obtułowicz, Aleksander Pastuszczak, Maciej Wojas-Pelc, Anna Level of inflammatory cytokines tumour necrosis factor α, interleukins 12, 23 and 17 in patients with psoriasis in the context of metabolic syndrome |
title | Level of inflammatory cytokines tumour necrosis factor α, interleukins 12, 23 and 17 in patients with psoriasis in the context of metabolic syndrome |
title_full | Level of inflammatory cytokines tumour necrosis factor α, interleukins 12, 23 and 17 in patients with psoriasis in the context of metabolic syndrome |
title_fullStr | Level of inflammatory cytokines tumour necrosis factor α, interleukins 12, 23 and 17 in patients with psoriasis in the context of metabolic syndrome |
title_full_unstemmed | Level of inflammatory cytokines tumour necrosis factor α, interleukins 12, 23 and 17 in patients with psoriasis in the context of metabolic syndrome |
title_short | Level of inflammatory cytokines tumour necrosis factor α, interleukins 12, 23 and 17 in patients with psoriasis in the context of metabolic syndrome |
title_sort | level of inflammatory cytokines tumour necrosis factor α, interleukins 12, 23 and 17 in patients with psoriasis in the context of metabolic syndrome |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6409868/ https://www.ncbi.nlm.nih.gov/pubmed/30858782 http://dx.doi.org/10.5114/ada.2018.73136 |
work_keys_str_mv | AT pirowskamagdalena levelofinflammatorycytokinestumournecrosisfactorainterleukins1223and17inpatientswithpsoriasisinthecontextofmetabolicsyndrome AT podoleckatarzyna levelofinflammatorycytokinestumournecrosisfactorainterleukins1223and17inpatientswithpsoriasisinthecontextofmetabolicsyndrome AT lipkogodlewskasylwia levelofinflammatorycytokinestumournecrosisfactorainterleukins1223and17inpatientswithpsoriasisinthecontextofmetabolicsyndrome AT sułowiczjoanna levelofinflammatorycytokinestumournecrosisfactorainterleukins1223and17inpatientswithpsoriasisinthecontextofmetabolicsyndrome AT brzewskipaweł levelofinflammatorycytokinestumournecrosisfactorainterleukins1223and17inpatientswithpsoriasisinthecontextofmetabolicsyndrome AT obtułowiczaleksander levelofinflammatorycytokinestumournecrosisfactorainterleukins1223and17inpatientswithpsoriasisinthecontextofmetabolicsyndrome AT pastuszczakmaciej levelofinflammatorycytokinestumournecrosisfactorainterleukins1223and17inpatientswithpsoriasisinthecontextofmetabolicsyndrome AT wojaspelcanna levelofinflammatorycytokinestumournecrosisfactorainterleukins1223and17inpatientswithpsoriasisinthecontextofmetabolicsyndrome |